In 2026, the success of a gastroenterology claim depends on the clinical narrative bridging the gap between a symptom and a surgical intervention
These findings suggest that cDPP3 may be of interest both as a biomarker and as a potential target in sepsis
By Donna Monthei, RDN, LD | Originally Published: May 7, 2025 | Medically Reviewed on June 18, 2026 First things first, lets do a quick recap on what these GLP-1 (glucagon-like peptide-1) receptor agonists actually do
The timeline varies based on the nature of the injury, the dosage prescribed, and individual biology
GLP-1, amylin, and multi-agonist compounds
Recently, several investigators further emphasized the significance of this contribution by showing that the protective and detrimental effects of various proteins in the CP-induced AKI model were mediated via modulation of necroptosis signaling